Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer

Ilaria De Stefano; Gian Franco Zannoni; Maria Grazia Prisco; Anna Fagotti; Lucia Tortorella; Giuseppe Vizzielli; Luca Mencaglia; Giovanni Scambia; Daniela Gallo

doi:10.1016/j.ygyno.2011.05.025

Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer

Ilaria De Stefano, Gian Franco Zannoni, Maria Grazia Prisco, Anna Fagotti, Lucia Tortorella, Giuseppe Vizzielli, Luca Mencaglia, Giovanni Scambia, Daniela Gallo

Villanova Hospital of Firenze

Risultato della ricerca: Contributo in rivista › Articolo

51 Citazioni (Scopus)

Abstract

In this study we investigated the prognostic value of estrogen receptor α (ERα), ERβ and progesterone receptor (PR) expression in 58 untreated advanced serous ovarian cancer patients. The study also included 12 macroscopically and histopathologically normal ovaries.

Lingua originale	Inglese
pagine (da-a)	573-579
Numero di pagine	7
Rivista	Gynecologic Oncology
Volume	122
Numero di pubblicazione	3
DOI	https://doi.org/10.1016/j.ygyno.2011.05.025
Stato di pubblicazione	Pubblicato - 2011

Keywords

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Cell Nucleus
Cisplatin
Cohort Studies
Cystadenocarcinoma
Cytoplasm
Disease-Free Survival
Estrogen Receptor alpha
Estrogen Receptor beta
Female
Humans
Immunohistochemistry
Middle Aged
Ovarian Neoplasms
Paclitaxel
Progesterone
Receptors
Serous

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.ygyno.2011.05.025

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{e2263710fa794b508475064a8723858c,

title = "Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer",

abstract = "In this study we investigated the prognostic value of estrogen receptor α (ERα), ERβ and progesterone receptor (PR) expression in 58 untreated advanced serous ovarian cancer patients. The study also included 12 macroscopically and histopathologically normal ovaries.",

keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Cell Nucleus, Cisplatin, Cohort Studies, Cystadenocarcinoma, Cytoplasm, Disease-Free Survival, Estrogen Receptor alpha, Estrogen Receptor beta, Female, Humans, Immunohistochemistry, Middle Aged, Ovarian Neoplasms, Paclitaxel, Progesterone, Receptors, Serous, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Cell Nucleus, Cisplatin, Cohort Studies, Cystadenocarcinoma, Cytoplasm, Disease-Free Survival, Estrogen Receptor alpha, Estrogen Receptor beta, Female, Humans, Immunohistochemistry, Middle Aged, Ovarian Neoplasms, Paclitaxel, Progesterone, Receptors, Serous",

author = "{De Stefano}, Ilaria and Zannoni, {Gian Franco} and Prisco, {Maria Grazia} and Anna Fagotti and Lucia Tortorella and Giuseppe Vizzielli and Luca Mencaglia and Giovanni Scambia and Daniela Gallo",

year = "2011",

doi = "10.1016/j.ygyno.2011.05.025",

language = "English",

volume = "122",

pages = "573--579",

journal = "Gynecologic Oncology",

issn = "1095-6859",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer

AU - De Stefano, Ilaria

AU - Zannoni, Gian Franco

AU - Prisco, Maria Grazia

AU - Fagotti, Anna

AU - Tortorella, Lucia

AU - Vizzielli, Giuseppe

AU - Mencaglia, Luca

AU - Scambia, Giovanni

AU - Gallo, Daniela

PY - 2011

Y1 - 2011

N2 - In this study we investigated the prognostic value of estrogen receptor α (ERα), ERβ and progesterone receptor (PR) expression in 58 untreated advanced serous ovarian cancer patients. The study also included 12 macroscopically and histopathologically normal ovaries.

AB - In this study we investigated the prognostic value of estrogen receptor α (ERα), ERβ and progesterone receptor (PR) expression in 58 untreated advanced serous ovarian cancer patients. The study also included 12 macroscopically and histopathologically normal ovaries.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carboplatin

KW - Cell Nucleus

KW - Cisplatin

KW - Cohort Studies

KW - Cystadenocarcinoma

KW - Cytoplasm

KW - Disease-Free Survival

KW - Estrogen Receptor alpha

KW - Estrogen Receptor beta

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Middle Aged

KW - Ovarian Neoplasms

KW - Paclitaxel

KW - Progesterone

KW - Receptors

KW - Serous

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carboplatin

KW - Cell Nucleus

KW - Cisplatin

KW - Cohort Studies

KW - Cystadenocarcinoma

KW - Cytoplasm

KW - Disease-Free Survival

KW - Estrogen Receptor alpha

KW - Estrogen Receptor beta

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Middle Aged

KW - Ovarian Neoplasms

KW - Paclitaxel

KW - Progesterone

KW - Receptors

KW - Serous

UR - https://publicatt.unicatt.it/handle/10807/3725

U2 - 10.1016/j.ygyno.2011.05.025

DO - 10.1016/j.ygyno.2011.05.025

M3 - Article

SN - 1095-6859

VL - 122

SP - 573

EP - 579

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 3

ER -

Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo